Removing B2m with Nanobodies
Among those on dialysis, a build up in the blood of Beta-2 microglobulin (B2m) is responsible for potentially crippling dialysis-related amyloidosis (DRA). Nanobodies are functional antibody fragments—and, used in a resin, they captured 17 times more B2m than in earlier studies, without affecting other blood proteins. Even better, the resin can be regenerated and used again. One day, this approach may be combined with dialysis to improve treatments.
Read the full article » | Posted 03-16-2020
Related Articles
- Global Wearable Artificial Kidney Market Expected to Grow Posted 07-12-2024
- Byonyks X1: a New, Small, Portable APD Machine Posted 06-14-2024
- The Public-Private ASN, DHSS, KidneyX Partnership is 5 Years Old This Year Posted 05-09-2024
- New Measure of Home Dialysis Dropout Posted 01-16-2024